Key Finding
Following discontinuation of GLP-1 receptor agonists, patients experienced significant rebound in weight (mean +4.13 kg), waist circumference, and HbA1c, suggesting that continuous treatment is likely required to sustain clinically meaningful metabolic benefits.
If you've heard about GLP-1 medications like semaglutide (Ozempic or Wegovy) for weight loss, you may be wondering what happens when people stop taking them. A new scientific review published in the Journal of General Internal Medicine looked at exactly that question.
Researchers analyzed data from five clinical trials involving 719 people who had taken GLP-1 medications for weight loss and blood sugar control, then stopped. They tracked what happened to weight, blood sugar, waist size, and blood pressure for at least six months after the drugs were discontinued.
The results were telling. While people who had taken GLP-1 medications still weighed about 5.7 kg (roughly 12.5 pounds) less than those who never took them, the benefits didn't hold up well on their own. After stopping the medication, participants regained an average of 4.13 kg, their waist measurements crept back up, and blood sugar levels climbed again. In other words, much of the progress made during treatment began to reverse once the medication stopped.
The researchers concluded that these medications likely need to be taken continuously to maintain their benefits — which raises real questions about long-term cost, access, and side effects for many patients.
This is where a holistic approach becomes relevant. Many people are exploring acupuncture and Traditional Chinese Medicine (TCM) as complementary tools to support healthy weight, blood sugar balance, and metabolic health. Research suggests acupuncture may help regulate appetite, reduce inflammation, and support hormonal balance — potentially helping patients maintain progress made through other interventions.
If you're navigating weight management or metabolic health, speaking with a licensed acupuncturist can help you explore safe, integrative options tailored to your individual needs.
This systematic review and meta-analysis (Journal of General Internal Medicine, 2024) evaluated the post-discontinuation durability of GLP-1 receptor agonist (GLP-1RA) therapy across 5 RCTs encompassing 719 patients, with a minimum follow-up of 6 months post-cessation. Compared to controls, GLP-1RA discontinuation still yielded net reductions in weight (MD: -5.70 kg), BMI (MD: -2.94 kg/m²), waist circumference (MD: -3.66 cm), HbA1c (SMD: -0.73), and systolic blood pressure (MD: -3.62 mmHg). However, significant rebound was observed post-discontinuation: weight (+4.13 kg), BMI (+0.84 kg/m²), WC (+3.64 cm), and HbA1c (SMD: +0.69). Net baseline-to-follow-up benefit remained modest (weight MD: -2.32 kg; BMI MD: -0.82 kg/m²). Clinically, these findings underscore the limited durability of GLP-1RA-induced metabolic improvements without continuous therapy. For TCM practitioners, this highlights an integrative opportunity — acupuncture protocols targeting appetite regulation, insulin sensitivity, and metabolic function may offer meaningful adjunctive support for patients cycling on or off GLP-1 therapy.
Browse our directory of verified licensed practitioners near you.
Find a practitioner →📌 A multi-strain probiotic combination of Bifidobacterium, Lacticaseibacillus, Lactobacillus, and Streptococcus (Mix10) produced the greatest weight reduction versus placebo (MD: -2.83 kg) and also improved HDL cholesterol levels in patients with obesity across a network meta-analysis of 47 randomized controlled trials.
📌 Body acupuncture combined with conventional treatment produced the greatest improvements in fasting blood glucose and HbA1c in type 2 diabetes patients, while auricular acupuncture best reduced postprandial blood glucose and laser acupuncture most effectively improved insulin resistance across 139 randomized controlled trials.
📌 Combining plum-blossom needling with Western medicine produced a significantly higher rate of symptom improvement in alopecia areata patients compared to Western medicine alone (RR 1.09, 95% CI 1.03–1.16), though evidence certainty was rated low.